Abstract: Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.
Type:
Grant
Filed:
February 6, 2019
Date of Patent:
August 17, 2021
Assignee:
Evelo Biosciences, Inc.
Inventors:
Brian Goodman, Baundauna Bose, Christopher J. H. Davitt, Maria Sizova, Sofia M. R. Carlton, Andrea Itano, Holly Ponichtera, Taylor A. Cormack, Kritika Ramani
Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
Type:
Grant
Filed:
November 16, 2017
Date of Patent:
August 17, 2021
Assignee:
Infectious Disease Research Institute
Inventors:
Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
Abstract: The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
July 20, 2021
Assignee:
Universidade do Porto—Reitoria
Inventors:
Paula Maria Das Neves Ferreira Da Silva, Pedro Jorge Fonseca Madureira
Abstract: Method and compositions using transition metal salts and/or ammonium chloride to liberate toxins and other molecules from cyanobacteria, useful for assaying for total cyanobacterial toxins in lakes, reservoirs and other waters.
Abstract: The present invention relates to novel hybrid peptides developed from the combination of membrane surface protein peptide fragments present in anaplasmosis microorganisms, and in particular, bacteria of the species Anaplasma marginale. The present invention further relates to hybrid peptide sets, compositions and kits comprising such novel hybrid peptides, their uses and methods of inducing immune response. Each hybrid peptide, according to the present invention, comprises two or more peptide fragments of amino acid sequences as defined in the present invention linked together by means of a spacer element. The combined peptide fragments are protein peptide fragments of MSP1, MSP1a, MSP1b, MSP2, MSP2-HRV, MSP3, OMP7, OMP8, VirB9 and VirB10.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
June 15, 2021
Assignees:
BIOTICK PESQUISA E DESENVOLVIMENTO TECNOLÓGICO LTDA., FUNDAÇÃO BUTANTAN
Inventors:
Ana Marisa Chudzinski-Tavassi, Bárbara Athayde Vaz Galväo da Silva, Kerly Fernanda Mesquita Pasqualoto, Leo Kei Iwai, Rafael Marques Porto
Abstract: Described herein are bacterial microcompartments shell proteins modified to stably incorporate iron-sulfur clusters. Such bacterial microcompartments shell proteins exhibit redox cycling and confer electron transfer functionality to bacterial microcompartment shells.
Type:
Grant
Filed:
October 16, 2019
Date of Patent:
June 15, 2021
Assignee:
Board of Trustees of Michigan State University
Inventors:
Cheryl A. Kerfeld, Clement Aussignargues
Abstract: The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.
Type:
Grant
Filed:
August 8, 2017
Date of Patent:
June 1, 2021
Assignee:
SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
Abstract: The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.
Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
June 1, 2021
Assignees:
The United States of America as represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
Inventors:
Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
Abstract: The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, elderly and immunocompromised individuals.
Abstract: Provided herein are immunogenic compositions containing recombinant proteins capable of presenting all, or antigenic portions of, the Eimeria maxima, Eimeria tenella, and Eimeria acervulina IMP1 protein in developing active immunity to, and control of, coccidiosis. Also provided are methodologies of using the immunogenic compositions for administration to poultry and other animals in the control of coccidiosis. Nanoparticle-conjugated rIMP1 immunogenic compositions and methods of making and using them are provided.
Type:
Grant
Filed:
January 11, 2019
Date of Patent:
May 11, 2021
Assignees:
The United States of America, as represented by The Secretary of Agriculture, Board of Trustees of Souther Illinois University
Abstract: The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising such Trypanosoma antigens, methods and uses for such Trypanosoma antigens and immunogenic compositions for treating a Trypanosoma-based disease.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
April 13, 2021
Assignee:
PepTcell Limited
Inventors:
Olga Pleguezuelos Mateo, Wilson Caparros-Wanderley, Gregory A. Stoloff
Abstract: The present invention provides S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides a comprehensive, unambiguous method of capsular typing based on whole genome sequencing and bioinformatics. This capsular typing approach can accurately identify serotypes even when strains possess novel capsular loci and can be used to determine which strains to include when formulating vaccines, including herd specific vaccines.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
April 6, 2021
Assignee:
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Abstract: Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO: 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.
Type:
Grant
Filed:
February 16, 2015
Date of Patent:
March 30, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Inventors:
Billy Hargis, Neil R. Pumford, Young Min Kwon, Sherryll Layton
Abstract: Described are a therapeutic monoclonal antibody specific for the Type Six Secretion System (T6SS) needle protein of Acinetobacter baumannii (A. baumannii) and methods of use. Specifically, the antibody specifically binds to hemolysin co-regulated protein (Hep). Further disclosed are methods of using an anti-Hep antibody for detecting A. baumannii in a sample as well as a mutant A. baumannii strain comprising a deletion or mutation in its genome such that said deletion or mutation interrupts the proper translation of its hep protein.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
March 30, 2021
Assignee:
The Government of The United States, Represented by the Secretary of the Army
Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
February 23, 2021
Assignees:
University of South Florida, Washington University, Case Western Reserve University
Inventors:
John H. Adams, Christopher L. King, Niraj H. Tolia, Edwin Chen, Nichole Diane Salinas, Miriam Thankam George, Francis B. Ntumngia, Samantha Jones Barnes
Abstract: Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.
Abstract: In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.